New mechanisms and targets in the treatment of bone fragility

Clinical Science

Volumn 112, Issue 1-2, 2007, Pages 77-91

  Martin, T John ^a   Seeman, Ego ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

Author keywords

Bone formation; Bone mineral density; Bone remodelling; Bone resorption; Osteoblast; Osteoclast; Osteoporosis

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCITRIOL; CALCIUM; CYTOKINE; ETIDRONIC ACID; FLUORIDE; GROWTH FACTOR; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D;

BONE DENSITY; BONE FRAGILITY; BONE REMODELING; CELL DIFFERENTIATION; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

BONE AND BONES; BONE DENSITY; BONE REMODELING; BONE RESORPTION; FEMALE; FRACTURES, BONE; HUMANS; MALE; OSTEOPOROSIS; PARATHYROID HORMONE; PATIENT SELECTION; RECEPTORS, PARATHYROID HORMONE;

EID: 33846332080     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20060046     Document Type: Review

References (92)

1. van Staa, T. P., Dennison, E. M., Leufkens, H. G. M. and Cooper, C. (2001) Epidemiology of fractures in England and Wales. Bone 29, 517-522
2. Compston, J. (2005) How to manage osteoporosis after the menopause. Best Pract. Res. Clin. Rheumatol. 19, 1007-1019
3. Delmas, P. D. (2002) Treatment of postmenopausal osteoporosis. Lancet 359, 2018-2023
4. Parfitt, A. M. (1996) Skeletal heterogeneity and the purposes of bone remodelling: implications for the understanding of osteoporosis. In Osteoporosis (Marcus, R., Feldman, D. and Kelsey, J., eds.), pp. 315-339, Academic Press, San Diego
5. Seeman, E. (2003) Periosteal bone formation: a neglected determinant of bone strength. N. Eng. J. Med. 349, 320-323
6. Lips, P., Courpron, P. and Meunier, P. J. (1978) Mean wall thickness of trabecular bone packets in the human iliac crest: changes with age. Calcif. Tissue Res. 10, 13-17
7. Vedi, S., Compston, J. E., Webb, A. and Tighe, J. R. (1982) Histomorphometric analysis of bone biopsies from the iliac crest of normal British subjects. Metab. Bone Dis. Relat. Res. 4, 231-236
8. Manolagas, S. C. (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21, 115-137
9. Croucher, P. I., Garrahan, N. J., Mellish, R. W. E. and Compston, J. E. (1991) Age-related changes in resorption cavity characteristics in human trabecular bone. Osteoporosis Int. 1, 257-261
10. Van der Linden, J. C., Homminga, J., Verhaar, J. A. N. and Weinans, H. (2001) Mechanical consequences of bone loss in cancellous bone. J. Bone Miner. Res. 16, 457-465
11. Suda, T., Takakashi, N., Udagawa, N., Jimi, E., Gillespie, M. T. and Martin, T. J. (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20, 345-357
12. Boyle, W. J., Simonet, W. S. and Lacey, D. L. (2003) Osteoclast differentiation and activation. Nature 423, 337-342
13. Rodan, G. A. and Martin, T. J. (2000) Therapeutic approaches to bone diseases. Science 289, 1508-1514
14. Ciarelli, T. E., Fyhrie, D. P. M and Parfitt, A. M. (2003) Effects of vertebral bone fragility and bone formation rate on the mineralization levels of cancellous bone from white females. Bone 32, 311-315
15. Qui, S., Rao, R. D., Saroj, I., Sudhaker, I., Palnitkar, S. and Parfitt, A. M. (2003) Reduced iliac cancellous osteocyte density in patients with osteoporotic vertebral fracture. J. Bone Miner. Res. 18, 1657-1663
16. Eriksen, E. F., Hodgson, S. F., Eastell, R., Cedel, S. L., O'Fallon, W. M. and Riggs, B. L. (1990) Cancellous bone remodeling in type I (postmenopausal) osteoporosis: Quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J. Bone Miner. Res. 5, 311-319
17. Arlot, M. E., Delmas, P. D., Chappard, D. and Meunier, P. J. (1990) Trabecular and endocortical bone remodelling in postmenopausal osteoporosis: comparison with normal postmenopausal women. Osteoporosis Int. 1, 41-49
18. Brown, J. P., Delmas, P. D., Malaval, L., Edouard, C., Chapuy, M. C. and Meunier, P. J. (1984) Serum bone gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet i, 1091-1093
19. Seeman, E., Hopper, J., Bach, L., Cooper, M., McKay, J. and Jerums, G. (1989) Reduced bone mass in the daughters of women with osteoporosis. N. Engl. J. Med. 320, 554-558
20. Duan, Y., Turner, C. H., Kim, B. T. and Seeman, E. (2001) Sexual dimorphism in vertebral fragility is more the results of gender differences in bone gain than bone loss. J. Bone Miner. Res. 16, 2267-2275
21. Delmas, P. D. (2000) How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis? Bone 27, 1-3
22. Parfitt, A. M. (1980) Morphological basis of bone mineral measurements: transient and steady state effects of treatment in osteoporosis. Miner. Electrolyte Metab. 4, 273-287
23. Borah, B., Dufresne, T. E., Chmielewski, P. A., Johnson, T. D., Chines, A. and Manhart, M. D. (2004) Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 34, 736-746
24. Meunier, P. J. and Boivin, G. (1997) Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications. Bone 21, 373-377
25. Boivin, G. Y., Chavassieux, P. M., Santora, A. C., Yates, J. and Meunier, P. J. (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27, 687-694
26. Gonnelli, S., Cepollaro, C., Pondrelli, C. et al. (1999) Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis. Calcif. Tissue Int. 65, 359-364
27. Seibel, M. J., Naganathan, V. and Grauer, A. (2004) Relationship between pre-treatment bone resorption and vertebral fractures in postmenopausal osteoporotic women treated with risedronate. J. Bone Miner. Res. 19, 323-329
28. Civitelli, R., Gonnelli, S., Zacchei, F. et al. (1988) Bone turnover in postmenopausal osteoporosis. J. Clin. Invest. 82, 1268-1274
29. Delmas, P. D. and Seeman, E. (2004) Changes in bone mineral density explain little of the reduction in vertebral or non-vertebral fracture risk with anti-resorptive therapy. Bone 34, 599-604
30. Johnell, O., Scheele, W. H., Lu, Y., Reginster, J. Y., Need, A. G. and Seeman, E. (2002) Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 87, 985-922
31. Rosen, C. J., Hochberg, M. C., Bonnick, S. L. et al. (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J. Bone Miner. Res. 20, 141-151
32. Sarkar, S., Mitlak, B. H., Wong, M., Stock, J. L., Black, D. M. and Harper, K. D. (2002) Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J. Bone Miner. Res. 17, 1-10
33. Watts, N. B., Cooper, C., Lindsay, R. et al. (2004) Relationship between changes in bone mineral density and vertebral fracture risk associated wtth risedronate. J. Clin. Densitom. 7, 255-261
34. Watts, N. B., Geusens, P., Barton, I. P. and Felsenberg, D. (2005) Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J. Bone Miner. Res. 20, 2097-2104
35. Roux, C., Seeman, E., Eastell, R. et al. (2004) Efficacy of risedronate on clinical vertebral fractures within six months. Curr. Med. Res. Opin. 20, 433-439
36. Meunier, P. J., Roux, C., Seeman, E. et al. (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 350, 459-468
37. Reginster, J. Y., Seeman, E., De Vernejoul, M.-C. et al. (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis TROPOS study. Strontium ranelate reduces the risk of non vertebral fractures in post-menopausal women with osteoporosis: Treatment Of Peripheral Osteoporosis (TROPOS) Study. J. Clin. Endocrinol. Metab. 90, 2816-2822
38. Arlot, M. E., Delmas, P. D., Burt-Pichat, B., Roux, J. P., Portero, N. and Meunier, P. J. (2005) The effects of strontium ranelate on bone remodeling and bone safety assessed by histomorphometry in patients with postmenopausal osteoporosis. J. Bone Miner. Res. 20 (Suppl. 1), abstract 1084
39. Seeman, E. and Delmas, P. D. (2006) Bone quality: the material and structural basis of the gain and loss of bone strength. N. Engl. J. Med. 354, 2250-2261
40. Mashiba, T., Hirano, T., Turner, C. H., Forwood, M. R., Johnston, C. C. and Burr, D. B. (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J. Bone Miner. Res. 15, 613-620
41. Boivin, G., Chavassieux, P. M., Santora, A. C., Yates, J. and Meunier, P. J. (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27, 687-694
42. Li, J., Mashiba, T. and Burr, D. B. (2001) Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif. Tissue Int. 69, 281-286
43. Komatsubara, S., Mori, S., Mashiba, T. et al. (2003) Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J. Bone Miner. Res. 18, 512-520
44. Whyte, M. P., Wenkert, D., Clements, K. L., McAlister, W. H. and Mumm, S. (2003) Brief report: Bisphosphonate-induced osteopetrosis. N. Engl. J. Med. 349, 457-463
45. Odvina, C. V., Zerwekh, J. E., Rao, D. S., Maaloof, N., Gottschalk, F. A. and Pak, C. Y. C. (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J. Clin. Endocrinol. Metab. 90, 1294-1301
46. Bone, H., Hosking, D., Devogelaer, J. P. et al. (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Eng. J. Med. 350, 1189-1199
47. Bekker, P. J., Holloway, D. L., Rasmussen, A. S. et al. (2004) A single dose placebo-controlled study of ASMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. 19, 1059-1066
48. 3 antagonists for the prevention and treatment of osteoporosis. J. Med. Chem. 47, 4829-4837
49. +-ATPase prevents bone loss in both thyroparathyroidechomized and ovariectomized rats. J. Clin. Invest. 106, 177-179
50. de Vernejoul, M. C. and Benichou, O. (2001) Human osteopetrosis and other sclerosing disorders: recent genetic developments. Calcif. Tissue Int. 69, 1-6
51. Schaller, S., Henriksen, K., Sviegaaret, C. et al. (2004) The chloride channel inhibitor NS3736 prevents bone resorption in ovariectomized rats without changing bone formation. J. Bone Miner. Res. 19, 1144-1153
52. Lark, M. W., Stroup, G. B., James, I. E. et al. (2002) A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat. Bone 30, 746-753
53. Sly, W. S., Whyte, M. P., Sundaram, V. et al. (1985) Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. N. Eng. J. Med. 313, 139-145
54. Neer, R. M., Arnaud, C. D., Zanchetta, J. R. et al. (2001) Effect of parathyroid hormone(1-134) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434-1441
55. Dempster, D. W., Cosman, F., Parisien, M., Shen, V. and Lindsay, R. (1993) Anabolic actions of parathyroid hormone on bone. Endocr. Rev. 14, 690-709
56. Frolik, C. A., Black, E. C., Cain, R. L. et al. (2003) Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 33, 372-379
57. Dobnig, H. and Turner, R. T. (1995) Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136, 3632-3638
58. Jilka, R. L., Weinstein, R. S., Bellido, T., Robertson, P., Parfitt, A. M. and Manolagas, S. C. (1999) Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. Invest. 104, 439-446
59. Karsenty, G. (2001) Minireview: transcriptional control of osteoblast differentiation. Endocrinology 142, 2731-2733
60. Krishnan, V., Moore, T. L., Ma, Y. L. et al. (2003) Parathyroid hormone bone anabolic action requires Cbfa1/Runx2-dependent signalling. Mol. Endocrinol. 17, 423-435
61. Bellido, T., Ali, A. A., Plotkin, L. I. et al. (2003) Proteasomal degradation of Runx 2 shortens parathyroid hormone-induced apoptotic signalling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J. Biol. Chem. 278, 50259-50272
62. Bellido, T., Ali, A. A., Gubrij, I. et al. (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes; a novel mechanism for hormonal control of ostioblastogenesis. Endocrinology 146, 4577-4583
63. Boyden, L. M., Mao, J., Belsky, J. et al. (2002) High bone density due to a mutation in LDL receptor-related protein 5. N. Engl. J. Med. 346, 1513-1521
64. Gong, Y., Slee, R. B., Fukai, N., et al. (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107, 513-523
65. Moon, R. T., Kohn, A. D., De Ferrari, G. V. and Kaykas, A. (2004) Wnt and β-catenin signalling; diseases and therapies. Nat. Rev. Genet. 5, 691-701
66. Kulkarni, N. H., Halladay, D. A., Miles, R. R. et al. (2005) Effects of parathyroid hormone on Wnt signalling pathway in bone. J. Cell. Biochem. 95, 1178-1190
67. Rawadi, G. and Roman, S. (2005) Wnt signalling pathway: a new target for the treatment of osteoporosis. Expert Opin. Ther. Targets 9, 1063-1077
68. Keller, H. and Kreissel, M. (2005) SOST is a target gene for PTH in bone. Bone 237, 148-158
69. Jiang, Y., Zhao, J. J., Mitlak, B. H., Wang, O., Genant, H. K. and Eriksen, E. F. (2003) Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J. Bone Miner. Res. 18, 1932-1941
70. Martin, T. J. (2004) Does bone resorption inhibition affect the anabolic response to parathyroid hormone? Trends Endocrinol. Metab. 15, 49-50
71. Seeman, E. and Delmas, P. D. (2001) Reconstructing the skeleton with intermittent parathyroid hormone. Trends Endocrinol. Metab. 12, 281-283
72. Ettinger, B., San Martin, J., Crans, G. and Pavo, I. (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J. Bone Miner. Res. 19, 745-751
73. Black, D. M., Greenspan, S. L., Ensrud, K. E. et al. (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349, 1207-1215
74. Finkelstein, J. S., Hayes, A., Hunzelman, J. L., Wyland, J. J., Lee, H. and Neer, R. M. (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med. 349, 1216-1226
75. Cosman, F., Nieves, J., Zion, M., Woelfert, L., Luckey, M. and Lindsay, R. (2005) Daily and cyclic parathyroid hormone in women receiving alendronate. N. Engl. J. Med. 353, 566-575
76. Martin, T. J. and Sims, N. A. (2005) Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol. Med. 11, 76-81
77. Black, D. M., Bilezikian, J. P., Ensrud, K. E. et al. (2005) One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N. Engl. J. Med. 353, 555-565
78. Martin, T. J., Moseley, J. M. and Williams, E. D. (1997) Parathyroid hormone-related protein: hormone and cytokine. J. Endocrinol. 154, S23-S37
79. Philbrick, W. M., Wysolmerski, J. J., Galbraith, S. et al. (1996) Defining the roles of PTHrP in normal physiology. Physiol. Rev. 76, 127-173
80. Hock, J. M., Fonseca, J., Gunness-Hey, M., Kemp, B. E. and Martin, T. J. (1989) Comparison of the anabolic effects of synthetic parathyroid hormone-related protein (PTHrP) 1-34 and PTH 1-34 on bone in rats. Endocrinology 125, 2022-2027
81. Everhart-Caye, M., Inzucchi, S. E., Gunness-Hey, J., Mitnick, M. A. and Stewart, A. F. (1996) Parathyroid hormone (PTH)-related protein (1-36) is equipotent to PTH(1-34) in humans. J. Clin. Endocrinol. Metab. 81, 199-120
82. 2+ receptor antagonists that stimulate secretion of parathyroid hormone, J. Pharmacol. Exp. Ther. 299, 323-331
83. Amizuka, N., Karaplis, A. C., Henderson, J. E. et al. (1996) Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal postnatal bone development. Dev. Biol. 175, 166-176
84. Kartsogiannis, V., Moseley, J., McKelvie, B. et al. (1997) Temporal expression of PTHrP during endochondral bone formation in mouse and intramembranous bone formation in an in vivo rabbit model. Bone 21, 385-391
85. Suda, N., Gillespie, M. T., Traianedes, K. et al. (1996) Expression of parathyroid hormone-related protein in cells of osteoblast lineage. J. Cell. Physiol. 166, 94-104
86. Amizuka, N., Warshawsky, H., Henderson, J. E., Goltzman, D. and Karaplis, A. C. (1994) Parathyroid hormone-related peptide-depleted mice show abnormal epiphyseal cartilage development and altered endochondral bone formation. J. Cell Biol. 126, 1661-1623
87. Miao, D., He, B., Jiang, Y. et al. (2005) Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J. Clin. Invest. 115, 2402-2411
88. Laupacis, A., Sackett, D. L. and Roberts, R. S. (1988) An assessment of clinically useful measures of the consequences of treatment. N. Engl. J. Med. 318, 1728-1733
89. Sornay-Rendu, E., Munoz, F., Garnero, P., Duboeuf, F. and Delmas, P. D. (2005) Identification of osteopenic women at high risk of fracture: the OFELY Study. J. Bone Miner. Res. 20, 1813-1819
90. Kanis, J. A., Johnell, O., Black, D. M. et al. (2003) Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 33, 293-300
91. Boutroy, S., Bouxsein, M. L., Munoz, F. and Delmas, P. D. (2005) In vivo assessment of trabecular microarchitecture by high-resolution peripheral quantitative computed tomography. J. Clin. Endocrinol. Metab. 90, 6508-6515
92. Garnero, P. and Delmas, P. D. (2004) Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J. Musculoskel. Neuronal Interact. 4, 50-63